<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942020000300002</article-id>
<article-id pub-id-type="doi">10.30827/ars.v61i3.13718</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Development and Optimization of Amoxicillin Floating Raft System to effectively treat Helicobacter pylori infection]]></article-title>
<article-title xml:lang="es"><![CDATA[Formulación y Optimización del Sistema Flotante de Amoxicilina para el tratamiento efectivo de la infección por Helicobacter pylori]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Kamsali]]></surname>
<given-names><![CDATA[Akhil]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bhargav]]></surname>
<given-names><![CDATA[Eranti]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Mounika]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ravi]]></surname>
<given-names><![CDATA[Manne]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chaithanya Barghav]]></surname>
<given-names><![CDATA[Gandla]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Subba Reddy]]></surname>
<given-names><![CDATA[Peddireddigari]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Raghavendra Institute of Pharmaceutical Education and Research Department of Pharmaceutics ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>India</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Raghavendra Institute of Pharmaceutical Education and Research RERDS-CPR, Formulation and Drug delivery division ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>India</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Chemtex Inc Biochemist ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>USA</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Strides Pharma Science Limited  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>India</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>09</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>09</month>
<year>2020</year>
</pub-date>
<volume>61</volume>
<numero>3</numero>
<fpage>163</fpage>
<lpage>168</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942020000300002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942020000300002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942020000300002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction:  The aim of the present study was to develop and to characterize the floating raft system (FRS) of Amoxicillin to enhance gastric residence time and drug release to target Helicobacter pylori effectively.  Method:  In the present study, guar gum, glyceryl monostearate (GMS), calcium carbonate were selected as factors. Gelation duration (h), floating lag time (min), and % Cumulative drug release (CDR) were selected as responses. 23 factorial design with replicates was selected for experimentation.  Results: It was observed that guar gum and GMS were the major factors affecting gelation duration, increase in the quantity of both guar gum and GMS increased gelation duration i.e., sustained gelation period (24 h). Floating time increased with an increase in the amount of guar gum and calcium carbonate, whereas an increase in the quantity of GMS decreased floating time. Guar gum, calcium carbonate, and GMS exhibited an antagonistic effect on % CDR. Contour plots were used to identify design space; further numerical analysis yielded 12 best solutions based on desirability. FRS exhibited greater AUCo-t, Cmax, tmax, and t1/2 when compared to marketed formulation approximately 2.30 folds enhancement and prolongation with a sustained release for greater than 24 h that might be due to better gelation.  Conclusions: It can be concluded that the floating raft system was successfully developed by the Design of experiment (DoE) application with fewer trails and by utilizing easily available excipients for better floating, gelation, and sustained delivery of the drug.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: El objetivo del presente estudio fue formular y caracterizar el Sistema Flotante (FRS, siglas en Inglés) de Amoxicilina para prolongar el tiempo de residencia gástrica y liberación del fármaco para el enfoque efectivo del Helicobacter pylori.  Método:  Para el presente estudio se seleccionaron como factores goma guar, Monoestearato de glicerilo (GMS), carbonato de calcio. Como reacciones, se seleccionaros el período de congelación (h), el lapso de flotación (min), y el porcentaje acumulado de liberación del fármaco (CDR). Para la experimentación se seleccionaron el diseño factorial 23 con réplicas.  Resultados:  Se observó que la goma guar y el GMS fueron los factores principales que afectaron el período de congelación y mostraron un efecto sinérgico (positivo). Mientras que la goma guar y el carbonato de calcio mostraron un efecto positivo y el GMS mostró un efecto antagónico (negativo) en el lapso de flotación. El porcentaje CDR mostró un efecto antagónico en todos los factores. Se emplearon curvas de nivel para identificar el diseño del espacio, análisis numéricos posteriores produjeron 12 soluciones óptimas en base a la deseabilidad. El FRS mostró un mayor AUCo-t, Cmax, tmaxy t1/2 cuando se comparó con la formulación comercial, aproximadamente 2.30 cambios múltiplos y prolongación con liberación sostenida por más de 24 h que pudo deberse a una mejor congelación.  Conclusiones:  Se puede concluir que el sistema flotante se desarrolló satisfactoriamente por la aplicación del Diseño de Experimentos (DoE) con menores ensayos y utilizando fácilmente los excipientes disponibles para una mejor flotación, congelación y suministro constante del fármaco.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Floating raft system]]></kwd>
<kwd lng="en"><![CDATA[Helicobacter pylori]]></kwd>
<kwd lng="en"><![CDATA[factorial Design]]></kwd>
<kwd lng="en"><![CDATA[Invivo studies]]></kwd>
<kwd lng="es"><![CDATA[Sistema flotante]]></kwd>
<kwd lng="es"><![CDATA[Helicobacter pylori]]></kwd>
<kwd lng="es"><![CDATA[diseño factorial]]></kwd>
<kwd lng="es"><![CDATA[estudios in vivo]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Helicobacter pylori and gastric càncer: factors that modulate disease risk]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wroblewski]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Peek]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Microbiol Rev]]></source>
<year>2010</year>
<volume>23</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>713-39</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Development of gastroretentive metronidazole floating raft system for targeting Helicobacter pylori]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abou Youssef]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Kassem]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[El-Massik]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Boraie]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Pharm]]></source>
<year>2015</year>
<volume>486</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>297-305</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Alginate rafts and their characterisation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hampson]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Farndale]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Strugala]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Sykes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jolliffe]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Dettmar]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Pharm]]></source>
<year>2005</year>
<volume>294</volume>
<numero>1-2</numero>
<issue>1-2</issue>
<page-range>137-47</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Development and characterization of Amoxicillin loaded floating microballoons for the treatment of Helicobacter pylori induced gastric ulcer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Awasthi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kulkarni]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Asian J Pharm]]></source>
<year>2013</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>174-80</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Alginate-antacid combinations: raft formation and gastric retention studies]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hampson]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Jolliffe]]></surname>
<given-names><![CDATA[IG]]></given-names>
</name>
<name>
<surname><![CDATA[Bakhtyari]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Sykes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Johnstone]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug Dev Ind Pharm]]></source>
<year>2010</year>
<volume>36</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>614-23</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Floating in situ gelling system for stomach site-specific delivery of clarithromycin to eradicate H.pylori]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rajinikanth]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mishra]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[J Control Release]]></source>
<year>2008</year>
<volume>125</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>33-41</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Formulation, release characteristics, and bioavailability study of gastroretentive floating matrix tablet and floating raft system of Mebeverine HCl]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nabarawi]]></surname>
<given-names><![CDATA[Mohamed AEl]]></given-names>
</name>
<name>
<surname><![CDATA[Mahmoud]]></surname>
<given-names><![CDATA[HTeaima]]></given-names>
</name>
<name>
<surname><![CDATA[El-Monem]]></surname>
<given-names><![CDATA[Rehab AAbd]]></given-names>
</name>
<name>
<surname><![CDATA[Nabarawy]]></surname>
<given-names><![CDATA[Nagla AEl]]></given-names>
</name>
<name>
<surname><![CDATA[Dalia]]></surname>
<given-names><![CDATA[AGaber]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug Des Devel Ther]]></source>
<year>2017</year>
<volume>11</volume>
<page-range>1081-93</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Gastroretentive raft liquid delivery system as a new approach to release extension for carriermediated drug]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Samar Abouelatta]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed Aboelwafa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Omaima El-Gazayerly]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug Deliv]]></source>
<year>2018</year>
<volume>25</volume>
<page-range>1161-74</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
